



AmeriHealth Caritas[™]

New Hampshire

To: AmeriHealth Caritas New Hampshire Providers

Date: May 12, 2020

Subject: FDA Guidance on Belviq[®], Belviq XR[®] (lorcaserin) by Eisai

Summary: The U.S. Food and Drug Administration (FDA) has provided the following guidance on Belviq and Belviq XR (lorcaserin). The FDA has requested that the manufacturer of Belviq and Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai Inc., has submitted a request to voluntarily withdraw the drug.

The complete news release can be located at <https://www.fda.gov/safety/medical-product-safety-information/belviq-belviq-xr-lorcaserin-eisai-drug-safety-communication-fda-requests-withdrawal-weight-loss-drug>.

Questions:

If you have questions about this communication, please contact AmeriHealth Caritas New Hampshire Provider Pharmacy Services at **1-888-765-6394 (TTY 1-855-809-9206)**.